ストックスクリーナーアプリを入手
2.71
2.52%
-0.07
前日終値:
$2.78
開ける：
$2.77
24時間の取引高:
1.02M
Relative Volume:
0.42
時価総額：
$63.92M
収益：
$155.00K
当期純損益:
$-30.01M
株価収益率:
-1.6228
EPS:
-1.67
ネットキャッシュフロー:
$-11.98M
1週間 パフォーマンス:
+11.98%
1か月 パフォーマンス:
-63.23%
6か月 パフォーマンス:
-67.97%
1年 パフォーマンス:
-68.00%
1日の値動き範囲:
$2.615
$2.83
1週間の範囲:
$2.27
$3.00
52週間の値動き範囲:
$1.89
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
名前
Inmune Bio Inc
セクター
電話
(858) 964-3720
住所
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
INMB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
2.71 | 75.73M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-01 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-01 | ダウングレード | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-21 | 開始されました | Alliance Global Partners | Buy |
| 2024-09-27 | 開始されました | Raymond James | Outperform |
| 2024-08-22 | 開始されました | Scotiabank | Sector Outperform |
| 2023-06-01 | 開始されました | Robert W. Baird | Outperform |
| 2022-05-24 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
| 2021-04-21 | 開始されました | B. Riley Securities | Buy |
| 2021-01-22 | 繰り返されました | Maxim Group | Buy |
| 2020-09-01 | 開始されました | BTIG Research | Buy |
| 2020-07-15 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Inmune Bio Inc (INMB) 最新ニュース
How does INmune Bio Inc. generate profit in a changing economyDynamic growth stocks - jammulinksnews.com
Why INmune Bio Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Metal.it
Inmune Bio Reveals Promising XPro™ Trial Results - TipRanks
What analysts say about INmune Bio Inc. stockConsistently high returns - PrintWeekIndia
Is INmune Bio Inc. a good long term investmentOutstanding capital growth - PrintWeekIndia
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at - GuruFocus
INmune Bio Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - PrintWeekIndia
INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met - TipRanks
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference - The Manila Times
INmune Bio to present additional Phase 2 Alzheimer’s trial data By Investing.com - Investing.com Canada
Is INMB more suitable for short-term or long-term investment? - AInvest
When (INMB) Moves Investors should Listen - news.stocktradersdaily.com
What drives INmune Bio Inc. stock priceRapid wealth accumulation - jammulinksnews.com
Is INmune Bio Inc. stock overhyped or has real potentialFree Stock Selection with 300% Return - Newser
What makes INmune Bio Inc. stock price move sharplyFree Investment Group - beatles.ru
How INmune Bio Inc. stock performs during market volatilityCapital Growth Picks - Newser
Cambridge Investment Research Advisors Inc. Makes New $180,000 Investment in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug Trial - MSN
Where are the Opportunities in (INMB) - news.stocktradersdaily.com
INmune Bio shares slide after Phase II Alzheimer’s trial misses endpoints - MSN
INmune Bio reverses early gains after stock offering - MSN
INmune Bio surges ahead of mid-stage trial readout for Alzheimer’s drug - MSN
INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low - MSN
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Benzinga
INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble - MSN
INmune Bio - The Pharma Letter
XPro™'s Subgroup Success: A Silver Lining in INmune Bio's Alzheimer's Setback - AInvest
INmune Bio's $19M Funding: A Lifeline or a Launchpad for Breakthroughs? - AInvest
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
(INMB) Proactive Strategies - news.stocktradersdaily.com
INmune Bio Shares Fall After Downgrade From BTIG Research - MarketScreener
INmune Bio Shares Plunge After Alzheimer's Trial Misses Target - Finimize
INmune Bio (INMB) Faces Significant Downgrade by Scotiabank | INMB Stock News - GuruFocus
A Drug-Trial Stock Sale - Bloomberg.com
INmune Bio stock downgraded by Raymond James after Alzheimer’s trial miss - Investing.com Australia
Inmune Bio Inc (INMB) 財務データ
収益
当期純利益
現金流量
EPS
Inmune Bio Inc (INMB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Tesi Raymond Joseph | President and CEO |
Sep 12 '24 |
Buy |
6.38 |
15,380 |
98,048 |
1,554,106 |
| Moss David J | Chief Financial Officer |
Sep 12 '24 |
Buy |
6.38 |
7,690 |
49,024 |
1,275,869 |
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):